Registering a CAGR of 8.61% over the forecast period of 2022-2027, the human growth hormone market is anticipated to reach the market value of US$ 7,567.74 million in the year 2027 from US$ 4,632.54 million in the year 2022.
The human growth hormone which is also known as somatotropin is a peptide hormone which is secreted by pituitary gland that regulates cell regeneration and repair, metabolism, reproduction and cell growth which contributes to complete human growth. Growth hormone levels in the human body are supposed to be suitable for normal growth and those can be controlled by elements like sleep, stress, exercise and low glucose levels. These hormones also help regulate muscle & bone growth, body composition, sugar & fat metabolism, body fluids and recovery from injury.
In humans, the deficiency of hormone is caused by pituitary glands that do not create enough concentration of human growth hormones. This particular deficiency can be treated by managing recombinant human growth hormones by subcutaneous injection. Several genetic disorders like turner syndrome and Prader-Willi syndrome can cause this deficiency too which can lead to shorter-than-average height and delayed puberty.
Top Key players in the Human Growth Hormone Market have been identified through secondary research, and their market shares have been determined through primary and secondary research. The global Human Growth Hormone Market is fragmented with a large number of small players operating worldwide. The companies referred in the market research report includes Novo Nordisk, Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology and others.
November 2020, GenSci (GenScience Pharmaceuticals), entered an exclusive agreement with Foresee Pharmaceuticals, for commercializing the latter’s FP-001 program, LMIS (Leuprolide Mesylate Injectable Suspension) –subcutaneous, ready-to-use 3-month and 6-month depot formulations or Camcevi. This agreement will be solely focusing on the Chinese market.
November 2020, Aeterna collaborated with Novo Nordisk, with the aim to boost the application scope of macimorelin that helps diagnose growth hormone deficiency, which is childhood-onset. The company believes that this area is considerably untapped and therefore, desires to explore the unmet needs. Aeterna is currently in the early stage of clinical safety as well as efficacy study, which focuses on analyzing Macimorelin for detection of CGHD.
Human Growth Hormone Market is segmented based on the type, applications, companies and regions.
By Type, Human Growth Hormone Market has been segmented into
By Application, Human Growth Hormone Market has been segmented into
Because of variables such as attractive reimbursement scenarios, established healthcare infrastructure, major government initiatives, and expanding healthcare awareness, North America is expected to account for the greatest share. Furthermore, the North American market benefits from enhanced access to novel medications due to the presence of important competitors in the region. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc. are some of the leading US-based competitors in the region, offering a wide range of human GH medicines.
Over the forecast period, Asia Pacific is expected to grow at a high rate. By acquiring permission and launching fresh goods, key companies aim to gain a significant market share in Asia Pacific potential countries such as Japan and China. For example, Novo Nordisk A/S, a Danish pharmaceutical company, began a phase III clinical trial of their HGH somapacitan, which is used to treat adult growth hormone insufficiency, in March 2017.
Report Attributes | Report Details |
Forecast Period 2022 to 2027 CAGR | CAGR of 8.61% during the review period (2022 to 2027). |
By Type |
|
By Application |
|
By Companies | Novo Nordisk, Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology and others. |
Regions Covered |
|
Countries Covered |
|
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2022 to 2027 |
Number of Pages | 121 |
Customization Available | Yes, the report can be customized as per your needs |
What is the study period of this market?
The Human Growth Hormone Market is studied from 2017 - 2027.
What is the growth rate of Human Growth Hormone Market?
The Human Growth Hormone Market is growing at a CAGR of 8.61% over the next 5 years.
Who are the leading key players in Human Growth Hormone Market?
Novo Nordisk, Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology and others.
What regions regions does this Human Growth Hormone Market report covers?
North America (the United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
What are the significant types of Human Growth Hormone Market?
Powder, Solvent
What are the significant Applications of Human Growth Hormone Market?
Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome, Prader-Willi Syndrome
All our reports are customizable to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report to your needs.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Reach us with your research requirements and we shall provide the optimum solution to suit your needs.
Discounts available for multiple report purchases.